Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2021 Financial Results and Provide Corporate Update
Xenon Pharmaceuticals (Nasdaq:XENE) will report its third quarter 2021 financial results on November 10, 2021, after U.S. market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Xenon Pharmaceuticals (Nasdaq:XENE) will report its third quarter 2021 financial results on November 10, 2021, after U.S. market close. A live conference call and webcast will take place at 4:30 pm ET to discuss these results and provide a corporate update. Investors can access the webcast through the company's website. As a clinical-stage biopharmaceutical company, Xenon focuses on developing therapies for neurological disorders, particularly epilepsy, addressing significant unmet medical needs.
Positive
- Focus on innovative therapeutics for neurological disorders, addressing unmet medical needs.
Negative
- None.
Details
News Market Reaction – XENE
The recorded move for XENE in the trading session of this news was +1.99%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BURNABY, British Columbia, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its third quarter 2021 financial and operating results after the close of U.S. financial markets on Wednesday, November 10, 2021.
- Xenon management will host a conference call and live audio webcast at 4:30 pm Eastern Time (1:30 pm Pacific Time) on Wednesday, November 10, 2021 to discuss the third quarter 2021 financial results and provide a corporate update. The webcast will be broadcast live on the Investors section of the Xenon website. To participate in the call, please dial (855) 779-9075, or (631) 485-4866 for international callers, and provide conference ID number 1244439.
The above listed dates and times are subject to change. Details on company presentations and webcasts can be found on the “Investors” section of Xenon's website at investor.xenon-pharma.com. When available, webcasts will be posted for replay following the event.
About Xenon Pharmaceuticals Inc.
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Investor/Media Contact:
Maria McClean
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.